Western blot analysis of extracts from NIH/3T3 cells, untreated (-) or treated with Human Platelet-Derived Growth Factor BB (hPDGF-BB) #8912 (100 ng/ml, 15 min; +) with or without pretreating the cells with PP2 (10 μM, 1 hr; +), using Phospho-Stat3 (Tyr705) (D3A7) XP® Rabbit mAb #9145 (upper), Stat3 (D1B2J) Rabbit mAb #30835 (middle), and β-Actin (D6A8) Rabbit mAb #8457 (lower).
Chemical structure of PP2.
PP2 is supplied as a lyophilized powder. For a 15 mM stock, reconstitute 5 mg of powder in 1.1 ml of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
Molecular Weight: 301.8 g/mol
Molecular Formula: C15H16CIN5
Solubility: Soluble in DMSO at 25 mg/ml or ethanol at 3 mg/ml with slight warming.
PP2 is a potent and selective inhibitor of Src-family kinases. This small molecule inhibits Lck (IC50 = 4 nM), Fyn (IC50 = 5 nM), and Hck (IC50 = 5 nM) with little to no effect on ZAP-70 (IC50 > 100 µM) and JAK2 (IC50 > 50 µM) (1). Members of the Src family are involved in the regulation of cellular excitability and synaptic plasticity. Inhibition of Src family nonreceptor protein tyrosine kinases (PTKs) can decrease epileptiform activity, making PP2 an important compound when studying epilepsy and antiepileptic therapies (2).
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.